Biomarkers of Renal Tumors: the Current State and Clinical Perspectives
详细信息 查看全文
- 作者：Marina O. Golovastova ; Dmitry O. Korolev ; Larisa V. Tsoy…
- 关键词：Renal cancer ; Markers ; Epigenetic regulations ; DNA methylation ; Cancer ; retina antigens ; Recoverin
- 刊名：Current Urology Reports
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：18
- 期：1
- 全文大小：
- 刊物主题：Urology; Nephrology;
- 出版者：Springer US
- ISSN：1534-6285
- 卷排序：18
文摘
Renal cell carcinoma (RCC) ranks the first death rate among the urogenital tumors, whereas its incidence follows the incidences of prostate and bladder cancer. The diagnosis of RCC at early stages allows immediately undertaking appropriate treatment, which significantly increases patients’ survival rate. Early and accurate diagnosis avoids inadequate treatment, provides the disease progression forecast, and permits to apply more efficient therapy. Unfortunately, the small renal tumors are usually asymptomatic resulting in the late diagnosis and, therefore, low efficacy of treatment. Thus, sensible and preventive biomarkers are essential for early RCC detection and monitoring of its progression. So far, many attempts were performed aimed at recognizing novel informative kidney tumor biomarkers applicable for early detection of the disease and possessing prognostic and predictive capabilities. This review summarizes recent advances in renal tumor biomarkers recognition, their diagnostic and prognostic values, and clinical feasibility.